EP2089014A4 - Omega-3-fettsäuren und mittel gegen dyslipidämie zur senkung des apo-b-spiegels - Google Patents

Omega-3-fettsäuren und mittel gegen dyslipidämie zur senkung des apo-b-spiegels

Info

Publication number
EP2089014A4
EP2089014A4 EP07852630A EP07852630A EP2089014A4 EP 2089014 A4 EP2089014 A4 EP 2089014A4 EP 07852630 A EP07852630 A EP 07852630A EP 07852630 A EP07852630 A EP 07852630A EP 2089014 A4 EP2089014 A4 EP 2089014A4
Authority
EP
European Patent Office
Prior art keywords
apo
omega
levels
reduction
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07852630A
Other languages
English (en)
French (fr)
Other versions
EP2089014A1 (de
Inventor
Roelof M L Rongen
Robert A Shalwitz
Douglas Kling
Ralph T Doyle Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reliant Pharmaceuticals Inc
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of EP2089014A1 publication Critical patent/EP2089014A1/de
Publication of EP2089014A4 publication Critical patent/EP2089014A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP07852630A 2006-10-10 2007-10-10 Omega-3-fettsäuren und mittel gegen dyslipidämie zur senkung des apo-b-spiegels Withdrawn EP2089014A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85028006P 2006-10-10 2006-10-10
PCT/US2007/021631 WO2008045465A1 (en) 2006-10-10 2007-10-10 Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels

Publications (2)

Publication Number Publication Date
EP2089014A1 EP2089014A1 (de) 2009-08-19
EP2089014A4 true EP2089014A4 (de) 2009-12-09

Family

ID=39283166

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07852630A Withdrawn EP2089014A4 (de) 2006-10-10 2007-10-10 Omega-3-fettsäuren und mittel gegen dyslipidämie zur senkung des apo-b-spiegels

Country Status (10)

Country Link
EP (1) EP2089014A4 (de)
JP (1) JP2010505956A (de)
KR (1) KR20090080070A (de)
CN (2) CN101553221A (de)
AU (1) AU2007307007A1 (de)
BR (1) BRPI0719182A2 (de)
CA (1) CA2672919A1 (de)
EA (2) EA018734B1 (de)
MX (1) MX2009003921A (de)
WO (1) WO2008045465A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
JP2010506920A (ja) * 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR101383006B1 (ko) 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh) * 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (de) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Verfahren zur behandlung von hypertriglyceridämie
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
EP4338805B1 (de) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaensäureethylester zur verwendung bei der verringerung des risikos eines nicht-fatalen herzinfarktes bei einer person in statin-therapie
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
JP6227535B2 (ja) * 2012-08-30 2017-11-08 株式会社三和化学研究所 脂質異常症の予防又は治療薬
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
MX369471B (es) * 2014-02-05 2019-11-08 Dezima Pharma B V Inhibidor de proteina de transferencia del ester de colesterilo (cetp) y composiciones farmaceuticas que comprenden el inhibidor para uso en el tratamiento o prevencion de enfermedades cardiovasculares.
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170643A1 (en) * 1999-10-26 2003-09-11 Edward Fisher Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes
WO2007011886A2 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589654C (en) * 2004-12-06 2016-02-16 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170643A1 (en) * 1999-10-26 2003-09-11 Edward Fisher Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes
WO2007011886A2 (en) * 2005-07-18 2007-01-25 Reliant Pharmaceuticals, Inc. Treatment with azetidinone-based cholesterol absorption inhibitors and omega-3 fatty acids and a combination product thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHAN ET AL: "Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia", DIABETES,, vol. 51, 1 January 2002 (2002-01-01), pages 2377 - 2386, XP008108930 *
DURRINGTON P N ET AL: "An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased trigycerides in simvastatin treated patients with coronary heart disease and persisting hyperlipidemia", HEART, BMJ, LONDON, GB, vol. 85, 1 January 2001 (2001-01-01), pages 544 - 548, XP003011854, ISSN: 1355-6037 *
NORDOY ET AL: "n-3 fatty acids as supplement to statins in the treatment of patients with combined hyperlipidemia'", ESSENTIAL FATTY ACIDS AND EICOSANOIDS: INVITED PAPERS FROM THEINTERNATIONAL CONGRESS, XX, XX, 1 January 1998 (1998-01-01), pages 256 - 261, XP008081086 *
See also references of WO2008045465A1 *

Also Published As

Publication number Publication date
CA2672919A1 (en) 2008-04-17
EA200970360A1 (ru) 2009-10-30
EA018734B1 (ru) 2013-10-30
JP2010505956A (ja) 2010-02-25
AU2007307007A1 (en) 2008-04-17
CN101553221A (zh) 2009-10-07
KR20090080070A (ko) 2009-07-23
BRPI0719182A2 (pt) 2014-10-21
CN101553220A (zh) 2009-10-07
MX2009003921A (es) 2009-08-31
WO2008045465A1 (en) 2008-04-17
EA200970359A1 (ru) 2009-10-30
EP2089014A1 (de) 2009-08-19

Similar Documents

Publication Publication Date Title
EP2089014A4 (de) Omega-3-fettsäuren und mittel gegen dyslipidämie zur senkung des apo-b-spiegels
EP2083815A4 (de) Statin und omega-3-fettsäuren zur reduzierung der apo-b-spiegel
EP2083622A4 (de) Omega-3-fettsäuren zur reduktion der lp-pla2-spiegel
EP1830830A4 (de) Omega-3-fettsäuren und dyslipidämisches mittel für die lipidtherapie
IL205362A0 (en) Medium - chain length fatty acids and glycerides as nephroprotection agents
EP1904049A4 (de) Mehrfach ungesättigte fettsäuren zur behandlung von demenz und prä-demenz-erkrankungen
IL183246A0 (en) Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP2061335A4 (de) Glyceridölzusammensetzung aus fischöl und verfahren zu ihrer herstellung
EP2120920A4 (de) Oxylipine aus langkettigen mehrfach ungesättigten fettsäuren sowie verfahren zu ihrer herstellung und verwendung
IL180602A0 (en) Composition containing statins and omega-3 fatty acids
IL190715A0 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
ZA200702280B (en) Fatty acid esters of alkanolamines and their use as softening agents
GB2443926B (en) Electronic candle and method of use
PL1755565T3 (pl) Miękka kapsułka żelatynowa zawierająca wielonienasycony kwas tłuszczowy omega-3
ZA200807341B (en) Fatty acid by-products and methods of using same
ZA200807296B (en) Fatty acid by-products and methods of using same
PL2214638T3 (pl) Kompozycja zawierająca wielonienasycone kwasy tłuszczowe i węgiel aktywny
PL2390338T3 (pl) Delta-8 desaturazy i ich zastosowanie w wytwarzaniu polinienasyconych kwasów tłuszczowych
EP1886988A4 (de) Intermolekulare verbindung eines fettsäuretriglycerids
EP2099295A4 (de) Prophylaxe und behandlung des vorhofflimmerns mit omega-3-fettsäuren
GB2444896B (en) Compositions comprising polyunsaturated fatty acids
EP1999238A4 (de) Freisetzungsmittel mit verseiften fett- und harzsäuren oder derivaten davon
ZA200810831B (en) Formulations with feruloyl glycerides and methods of preparation
DE502007000267D1 (de) Mehrfach ungesättigte Fettsäuren enthaltendes Pulver
PL386608A1 (pl) Sposób otrzymywania nienasyconych pochodnych wyższych kwasów tłuszczowych oraz instalacja do realizacji tego sposobu

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090507

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

A4 Supplementary search report drawn up and despatched

Effective date: 20091110

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/366 20060101ALI20091104BHEP

Ipc: A61P 9/00 20060101ALI20091104BHEP

Ipc: A61P 3/06 20060101ALI20091104BHEP

Ipc: A61K 31/351 20060101ALI20091104BHEP

Ipc: A61K 31/232 20060101ALI20091104BHEP

Ipc: A61K 31/20 20060101AFI20080523BHEP

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20090507

17Q First examination report despatched

Effective date: 20100212

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100824